ProCE Banner Activity

Emerging Treatment Options for Patients With CLL

Clinical Thought
Review an expert discussion of investigational treatment strategies for patients with chronic lymphocytic leukemia, including novel BTK and PI3K inhibitors, combination treatment with BTK and BCL-2 inhibitors, and CAR T-cell therapy.

Released: April 21, 2022

Expiration: April 20, 2023

No longer available for credit.

Share

Faculty

Shuo Ma

Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Shuo Ma, MD, PhD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, BeiGene, Janssen, and Pharmacyclics and funds for research support from AbbVie, AstraZeneca, BeiGene, Janssen, Juno, Loxo, Pharmacyclics, and TG Therapeutics.